{"@context":{"@vocab":"https://schema.org/","dcterms":"http://purl.org/dc/terms/","prov":"http://www.w3.org/ns/prov#"},"@type":"ItemList","@id":"https://api.morvs.ai/api/v1/entity/LYEL/timeline","_source":{"data_provider":"AI Analytics","brand_name":"MORVS","brand_url":"https://morvs.ai/","data_provider_url":"https://api.morvs.ai","license":"https://api.morvs.ai/license","usage_info":"https://api.morvs.ai/license","rights":"Source-specific terms apply; free or keyless access does not alter them.","generated_at":"2026-09-29T05:38:17.083Z","methodology_url":"https://api.morvs.ai/datasets/","primary_sources":{"sec.*":"https://www.sec.gov/edgar","fda.*":"https://api.fda.gov/","contracts":"https://api.usaspending.gov/","clinical.trials":"https://clinicaltrials.gov/","lobbying.filings":"https://lda.senate.gov/","epa.facilities":"https://echo.epa.gov/","court.dockets":"https://www.courtlistener.com/","cfpb.complaints":"https://www.consumerfinance.gov/data-research/consumer-complaints/","nih.grants":"https://api.reporter.nih.gov/","fed.enforcement":"https://www.federalreserve.gov/supervisionreg/enforcementactions.htm","nhtsa.recalls":"https://api.nhtsa.gov/recalls/"}},"entity":{"entity_id":1943,"canonical_name":"Lyell Immunopharma, Inc.","cik":"0001806952","uei":null,"lei":null,"duns":null,"ticker":"LYEL"},"window_days":180,"min_importance":0,"sources_queried":["sec.filings","sec.insider","sec.form144","sec.13dg","fda.recalls","fda.labels","contracts","clinical.trials","lobbying.filings","epa.facilities","uspto.patents","court.dockets","cfpb.complaints","nih.grants","fed.enforcement","nhtsa.recalls","doj.press","dol.form5500"],"importance_reference":{"fda.recall Class I":100,"clinical trial terminated":80,"securities class action":80,"antitrust suit":75,"schedule 13D":75,"patent litigation":70,"form144 large ($50M+)":75,"10-K restatement":75,"phase3 trial completed":70,"EPA significant violator":70,"phase3 trial in progress":60,"insider purchase":50,"phase2 trial":45,"8-K":35,"lobbying filing":30,"fda.label":30,"phase1 trial":30,"fda.recall Class III":25},"vertical_counts":{"sec":34},"count":34,"timeline":[{"ts":"2026-08-11","kind":"sec.filing","form_type":"4","title":"4 — Lyell Immunopharma, Inc. — 2026-08-11","url_slug":"/sec/cik-0001806952/4/0001866154-26-000004","accession_number":"0001866154-26-000004","importance":30},{"ts":"2026-08-11","kind":"sec.filing","form_type":"4","title":"4 — Lyell Immunopharma, Inc. — 2026-08-11","url_slug":"/sec/cik-0001806952/4/0001907345-26-000004","accession_number":"0001907345-26-000004","importance":30},{"ts":"2026-08-11","kind":"sec.filing","form_type":"4","title":"4 — Lyell Immunopharma, Inc. — 2026-08-11","url_slug":"/sec/cik-0001806952/4/0002095702-26-000005","accession_number":"0002095702-26-000005","importance":30},{"ts":"2026-08-10","kind":"sec.insider.s","reporter":"Bulis Veronica Sanchez","title":"VP, Corporate Controller","shares":621,"price_per_share":14.34,"usd_value":8905,"security_title":"Common Stock","importance":35.00890514},{"ts":"2026-08-10","kind":"sec.insider.s","reporter":"Seely Lynn","title":"President and CEO","shares":390,"price_per_share":14.34,"usd_value":5593,"security_title":"Common Stock","importance":35.0055926},{"ts":"2026-08-10","kind":"sec.insider.s","reporter":"Lee Gary K.","title":"Chief Scientific Officer","shares":131,"price_per_share":14.34,"usd_value":1879,"security_title":"Common Stock","importance":35.00187854},{"ts":"2026-08-10","kind":"sec.insider.s","reporter":"Hill Stephen J.","title":"Chief Operating Officer","shares":89,"price_per_share":14.34,"usd_value":1276,"security_title":"Common Stock","importance":35.00127626},{"ts":"2026-07-21","kind":"sec.filing","form_type":"EFFECT","title":"EFFECT — Lyell Immunopharma, Inc. — 2026-07-21","url_slug":"/sec/cik-0001806952/effect/9999999995-26-002375","accession_number":"9999999995-26-002375","importance":30},{"ts":"2026-07-20","kind":"sec.filing","form_type":"4","title":"4 — Lyell Immunopharma, Inc. — 2026-07-20","url_slug":"/sec/cik-0001806952/4/0001140361-26-028955","accession_number":"0001140361-26-028955","importance":30},{"ts":"2026-07-17","kind":"sec.insider.s","reporter":"Innovative Cellular Therapeutics Holdings Ltd","title":null,"shares":10,"price_per_share":13.7,"usd_value":137,"security_title":"Common Stock","importance":35.000137},{"ts":"2026-07-17","kind":"sec.filing","form_type":"4","title":"4 — Lyell Immunopharma, Inc. — 2026-07-17","url_slug":"/sec/cik-0001806952/4/0001140361-26-028846","accession_number":"0001140361-26-028846","importance":30},{"ts":"2026-07-16","kind":"sec.insider.s","reporter":"Innovative Cellular Therapeutics Holdings Ltd","title":null,"shares":10,"price_per_share":13.73,"usd_value":137,"security_title":"Common Stock","importance":35.0001373},{"ts":"2026-07-13","kind":"sec.filing","form_type":"S-3","title":"S-3 — Lyell Immunopharma, Inc. — 2026-07-13","url_slug":"/sec/cik-0001806952/s-3/0001193125-26-302132","accession_number":"0001193125-26-302132","importance":30},{"ts":"2026-07-01","kind":"sec.filing","form_type":"4","title":"4 — Lyell Immunopharma, Inc. — 2026-07-01","url_slug":"/sec/cik-0001806952/4/0001140361-26-027140","accession_number":"0001140361-26-027140","importance":30},{"ts":"2026-06-29","kind":"sec.insider.j","reporter":"Innovative Cellular Therapeutics Holdings Ltd","title":null,"shares":76000,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-18","kind":"sec.filing","form_type":"3","title":"3 — Lyell Immunopharma, Inc. — 2026-06-18","url_slug":"/sec/cik-0001806952/3/0001140361-26-025740","accession_number":"0001140361-26-025740","importance":30},{"ts":"2026-06-18","kind":"sec.filing","form_type":"4","title":"4 — Lyell Immunopharma, Inc. — 2026-06-18","url_slug":"/sec/cik-0001806952/4/0001140361-26-025796","accession_number":"0001140361-26-025796","importance":30},{"ts":"2026-06-18","kind":"sec.filing","form_type":"SCHEDULE 13G/A","title":"SCHEDULE 13G/A — Lyell Immunopharma, Inc. — 2026-06-18","url_slug":"/sec/cik-0001806952/schedule-13g-a/0001140361-26-025769","accession_number":"0001140361-26-025769","importance":30},{"ts":"2026-06-15","kind":"sec.filing","form_type":"8-K","title":"8-K — Lyell Immunopharma, Inc. — 2026-06-15","url_slug":"/sec/cik-0001806952/8-k/0001193125-26-271071","accession_number":"0001193125-26-271071","importance":35},{"ts":"2026-06-15","kind":"sec.filing","form_type":"4","title":"4 — Lyell Immunopharma, Inc. — 2026-06-15","url_slug":"/sec/cik-0001806952/4/0001866154-26-000003","accession_number":"0001866154-26-000003","importance":30},{"ts":"2026-06-15","kind":"sec.filing","form_type":"4","title":"4 — Lyell Immunopharma, Inc. — 2026-06-15","url_slug":"/sec/cik-0001806952/4/0001907345-26-000003","accession_number":"0001907345-26-000003","importance":30},{"ts":"2026-06-15","kind":"sec.filing","form_type":"4","title":"4 — Lyell Immunopharma, Inc. — 2026-06-15","url_slug":"/sec/cik-0001806952/4/0002095702-26-000004","accession_number":"0002095702-26-000004","importance":30},{"ts":"2026-06-15","kind":"sec.insider.j","reporter":"Innovative Cellular Therapeutics Holdings Ltd","title":null,"shares":66500,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-15","kind":"sec.insider.66500","reporter":"Innovative Cellular Therapeutics Holdings Ltd","title":null,"shares":66500,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-12","kind":"sec.filing","form_type":"4","title":"4 — Lyell Immunopharma, Inc. — 2026-06-12","url_slug":"/sec/cik-0001806952/4/0001887762-26-000002","accession_number":"0001887762-26-000002","importance":30},{"ts":"2026-06-11","kind":"sec.filing","form_type":"4","title":"4 — Lyell Immunopharma, Inc. — 2026-06-11","url_slug":"/sec/cik-0001806952/4/0001959742-26-000002","accession_number":"0001959742-26-000002","importance":30},{"ts":"2026-06-10","kind":"sec.insider.s","reporter":"Shook David","title":"Chief Medical Officer","shares":1977,"price_per_share":12.64,"usd_value":24989,"security_title":"Common Stock","importance":35.02498928},{"ts":"2026-05-11","kind":"sec.insider.s","reporter":"Seely Lynn","title":"President and CEO","shares":388,"price_per_share":18.91,"usd_value":7337,"security_title":"Common Stock","importance":35.00733708},{"ts":"2026-05-11","kind":"sec.insider.s","reporter":"Bulis Veronica Sanchez","title":"VP, Corporate Controller","shares":217,"price_per_share":18.91,"usd_value":4103,"security_title":"Common Stock","importance":35.00410347},{"ts":"2026-05-11","kind":"sec.insider.s","reporter":"Lee Gary K.","title":"Chief Scientific Officer","shares":130,"price_per_share":18.92,"usd_value":2460,"security_title":"Common Stock","importance":35.0024596},{"ts":"2026-05-11","kind":"sec.insider.s","reporter":"Hill Stephen J.","title":"Chief Operating Officer","shares":89,"price_per_share":18.92,"usd_value":1684,"security_title":"Common Stock","importance":35.00168388},{"ts":"2026-05-08","kind":"sec.filing","form_type":"SCHEDULE 13G/A","title":"SCHEDULE 13G/A — Lyell Immunopharma, Inc. — 2026-05-08","url_slug":"/sec/cik-0001806952/schedule-13g-a/0001168404-26-000021","accession_number":"0001168404-26-000021","importance":30},{"ts":"2026-04-13","kind":"sec.filing","form_type":"CORRESP","title":"CORRESP — Lyell Immunopharma, Inc. — 2026-04-13","url_slug":"/sec/cik-0001806952/corresp/0001193125-26-151895","accession_number":"0001193125-26-151895","importance":30},{"ts":"2026-04-08","kind":"sec.filing","form_type":"UPLOAD","title":"UPLOAD — Lyell Immunopharma, Inc. — 2026-04-08","url_slug":"/sec/cik-0001806952/upload/0000000000-26-003547","accession_number":"0000000000-26-003547","importance":30}]}